Oral Calcium Tolerance Test in Extensive Psoriasis Treated with Topical Calcipotriol

Gumowski‐Sunek, D.; Rizzoli, René; Saurat, Jean‐Hilaire

doi:10.1159/000246633

Cited by 9 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a subsequent study by the same group, 10 patients were treated with up to 95 g calcipotriol ointment (50 µg/g) per week (mean use: 90 g/week) for 6.5 weeks. As in the previous study, no significant changes were demonstrated in a wide variety of parameters of systemic calcium homoeostasis, including an oral calcium test [10]. …”

Section: Introductionmentioning

confidence: 67%

Safety and Efficacy of Combined High-Dose Treatment with Calcipotriol Ointment and Solution in Patients with Psoriasis

Kerkhof¹,

Green²,

Hamberg³

et al. 2002

Dermatology

View full text Add to dashboard Cite

Background: In the vast majority of psoriatic patients, psoriatic lesions are localised on the body as well as on the scalp. Therefore, safety data on the combined use of calcipotriol in lotion and calcipotriol in ointment are needed. Objective: This study investigated the effect of high-dose treatment with a combination of calcipotriol ointment and scalp solution on calcium metabolism, indices of bone turnover and PASI in patients with extensive psoriasis. Methods: Following a 2-week wash-out period, 88 patients were randomised to 4 weeks of treatment with either calcipotriol ointment/scalp solution (80–100 g/week and 30–50 ml/week, respectively; n = 41) or with a dithranol/tar regimen (n = 47). Patients were seen at weeks 1, 2 and 4 during treatment and 1 week following cessation of treatment. Results: No significant differences at the end of treatment were found between the 2 groups with respect to 24-hour urinary excretion of calcium (expressed as calcium/creatinine ratio), phosphate or pyridinoline, serum concentrations of calcium (albumin corrected), creatinine, phosphate, parathyroid hormone, 25-hydroxyvitamin D₃, 1,25-dihydroxyvitamin D₃, osteocalcin, alkaline phosphatase (total and bone-specific iso-enzymes) or 1-collagen telopeptide. At the end of treatment, the psoriasis area and severity index had decreased by 57.4% in the calcipotriol group and by 36.1% in the dithranol/tar group (p = 0.004). Investigators’ and patients’ assessments of overall efficacy also favoured treatment with calcipotriol (p < 0.001). Conclusion: The combined use of calcipotriol ointment/scalp solution did not affect the indices of calcium metabolism or bone turnover and was significantly more effective than dithranol/tar in reducing disease severity and extent in patients with extensive psoriasis.

show abstract

Section: Introductionmentioning

confidence: 67%

Safety and Efficacy of Combined High-Dose Treatment with Calcipotriol Ointment and Solution in Patients with Psoriasis

Kerkhof¹,

Green²,

Hamberg³

et al. 2002

Dermatology

View full text Add to dashboard Cite

show abstract

“…[7][8][9]13] [14][15][16][17] • Induces cell differentiation in vitrd8-1o. 13,18,19] and in patients with psoriasis [16.17.20] • Binds to calcitriol receptors [7'9,13] • Modifies levels of immunological and inflammatory mediators: -down-regulates or lowers levels of interleukins (IL-1, IL·6), [21,22] interleukin-8 receptors, [23] T cells (CD3-t, CD4+, CD6+ and CD8+), [16,24,25] cell adhesion molecules (ICAM-1, ELAM-1, LFA-1, VLA-3 and VLA_6) [24.26] and the plasminogen system [27] -up-regulates or increases levels of NGF, [28] TGF_~, [29,30] TGF-~ binding protein [30] and calcitriol receptors [31] • Less potent effect than calcitriol on calcium homeostasis in rats [8,9,32] and humans [33][34][35][36][37][38] Abbreviations: ELAM = endothelial leucocyte molecule; ICAM = intracellular adhesion molecule; LFA = lymphocyte function antigen; NGF = nerve growth factor; TGF = transforming growth factor; VLA = very late antigen.…”

Section: Effects On Cell Proliferation and Differentiationmentioning

confidence: 99%

Calcipotriol

Lea¹,

Goa²

1996

Clin. Immunother.

View full text Add to dashboard Cite

SynopsisCalcipotriol (calcipotriene) is a vitamin D3 analogue which inhibits cell proliferation. enhances cell differentiation and appears to influence immunological fa ctors which may playa role in the origins o/psoriasis. In patients with chronic Calcipotriol: A Review Overview of Pharmacological Properties Therapeutic Efficacy plaque psoriasis, twice-daily topical calcipotriol 50 flglg is more effective than unmedicated vehicle, betamethasone (betamethasone valerate), fiuocinonide, dithranol (anthralin) and coal tar in patients with nonscalp psoriasis; however; patients with scalp psoriasis respond better to betamethasone than calcipotriol. In the treatment of patients with severe psoriasis, calcipotriol used together with cyclosporin or psoralen ultraviolet A yields superior results to those achieved with either regimen alone. The efficacy of calcipotriol demonstrated in short term trials is sustained in noncomparative studies of up to 1 year in duration. Data from several clinical trials involving nearly 2000 patients show that calcipotriol is well tolerated, the most common adverse events being mild and transient irritation of lesions or peri Ie siona I skin which occur in 15.1 to 25.8% of patients. At recommended dosages hypercalcaemia and hypercalciuria are very rare. Calcipotriol is better tolerated than short-contact dithranol, but causes more adverse events than betamethasone particularly in patients with scalp psoriasis. 231

show abstract

“…Furthermore, potent hexafluoride analogues can reduce the breast cancer incidence and burden in N-nitroso-N-methylurea-treated rats (39). One area in which the therapeutic potential of vitamin D 3 has been realized is in the treatment of psoriasis, where the topical application of potent analogues, including calcipotriene (Dovonex), controls the disease and does not significantly interfere with serum calcium levels (40).…”

mentioning

confidence: 99%